Title: Regeneron Pharmaceuticals Inc (REGN) 10K Annual Reports & 10Q SEC Filings
URL: https://last10k.com/sec-filings/regn

HOME


LOGIN


PREMIUM


FREE TRIAL


SEC FILINGS


STOCK SCREENERS


EARNINGS


TRENDING


STOCKTWITS


INSIDER TRADING


SENTIMENT ANALYSIS


MANAGER PORTFOLIOS


LATE CORPORATE NEWS






				 



Regeneron Pharmaceuticals, Inc. (REGN) SEC Filing 10-K Annual Report for the fiscal year ending Sunday, December 31, 2023


Home
SEC Filings
Regeneron Pharmaceuticals Inc (REGN)
10-K Annual Report Mon Feb 05 2024






SEC Filings



 
REGN Valuations





Intrinsic Value





Financial Stability





Financial Ratios





Insider Trades





Manager Portfolios





Notifications





 
REGN Annual Reports
				  





10-K Annual Report February 2024


PDF

PDF


Select PDF Feature:
Include Exhibits
Highlight YoY Changes
Highlight Sentiment

10-K Only


Word
Excel
CSV


Table of Contents
Business
Risk Factors
Unresolved Staff Comments
Cybersecurity
Properties
Legal Proceedings
Mine Safety Disclosures
and Issuer Purchases of Equity Securities

Management's Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Principal Accountant Fees and Services
Exhibits and Financial Statement Schedules
Form 10K Summary
SIGNATURE PAGE
Table of








									10-K Annual Report February 2023																






									10-K Annual Report February 2022																






									10-K Annual Report February 2021																






									10-K Annual Report February 2020																






									10-K Annual Report February 2019																






									10-K Annual Report February 2018																






									10-K Annual Report February 2017																






									10-K Annual Report February 2016																






REGN Quarterly Reports
				  





									10-Q Quarterly Report August 2024																






									10-Q Quarterly Report May 2024																






									10-Q Quarterly Report November 2023																






									10-Q Quarterly Report August 2023																






									10-Q Quarterly Report May 2023																






									10-Q Quarterly Report November 2022																






									10-Q Quarterly Report August 2022																






									10-Q Quarterly Report May 2022																






									10-Q Quarterly Report November 2021																






									10-Q Quarterly Report August 2021																






REGN Corporate News
				  





									Earnings Release																	October 2024







									Earnings ReleaseFinancial Exhibit																	August 2024







									Earnings Release																	July 2024







									Vote of Security Holders																	June 2024







									Earnings ReleaseFinancial Exhibit																	May 2024







									Earnings ReleaseFinancial Exhibit																	February 2024







									Event for Officers																	January 2024







									Earnings ReleaseFinancial ExhibitRegulated Disclosure																	January 2024







									Earnings ReleaseFinancial Exhibit																	November 2023







									Earnings Release																	October 2023













Last10K.com | 10-K Annual Report Mon Feb 05 2024






Regeneron Pharmaceuticals Inc


													CIK: 872589
																										Ticker: REGN




Earnings Press Release
 10-K Annual Report
 10-K YoY Changes
 Annual Proxy




Regeneron Pharmaceuticals Inc

HISTORY
TOOLS


CIK: 872589
Ticker: REGN




Exhibit 99.1  Press ReleaseRegeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results•Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding RonapreveTM(a)(b), revenues increased 14%•Full year 2023 revenues increased 8% to $13.12 billion versus full year 2022; excluding Ronapreve(a), revenues increased 12%•Fourth quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 31% to $3.22 billion versus fourth quarter 2022; full year 2023 Dupixent global net sales increased 33% to $11.59 billion versus 2022•Fourth quarter 2023 U.S. net sales for EYLEA® HD and EYLEA® were $1.46 billion, including $123 million from EYLEA HD; full year 2023 U.S. net sales for EYLEA HD and EYLEA were $5.89 billion, including $166 million from EYLEA HD following its August 2023 FDA approval•Fourth quarter 2023 Libtayo® global net sales increased 44% to $244 million versus fourth quarter 2022; full year 2023 Libtayo global net sales increased 50% to $869 million versus 2022(f)•Fourth quarter 2023 GAAP diluted EPS of $10.19 and non-GAAP diluted EPS(a) of $11.86; includes unfavorable $0.21 impact from acquired IPR&D charge•Dupixent sBLA for chronic obstructive pulmonary disease (COPD) with type 2 inflammatory phenotype and linvoseltamab BLA for multiple myeloma submitted to FDATarrytown, New York (February 2, 2024) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2023 and provided a business update."2023 marked another year of exceptional accomplishments for Regeneron as we further diversified our revenue base and made important progress in our robust R&D pipeline," said Leonard S. Schleifer, M.D., Ph.D., Board Co-Chair, President and Chief Executive Officer of Regeneron. "In 2024, we plan to build on this momentum with continued growth of our breakthrough products Dupixent and EYLEA HD while we bring additional new therapies to market and advance our growing pipeline. Lastly, I want to congratulate our Chief Financial Officer, Bob Landry, on the occasion of his retirement and thank him for his significant contributions to Regeneron during his ten years with the Company."1The following information was filed by Regeneron Pharmaceuticals Inc (REGN) on Friday, February 2, 2024 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release. 

Please wait while we load the requested 10-K report or click the link below:https://last10k.com/sec-filings/report/872589/000180422024000009/regn-20231231.htm


View differences made from one year to another to evaluate Regeneron Pharmaceuticals Inc's financial trajectory





Sample 10-K Year-over-Year (YoY) Comparison



Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Regeneron Pharmaceuticals Inc.

Continue







Assess how Regeneron Pharmaceuticals Inc's management team is paid from their Annual Proxy





Screenshot example of actual Proxy Statement




Regeneron Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2024 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors


Continue














SEC Filing Tools




 Sentiment
 Sections
 Exhibits
 Stats


 



 Rating					
Learn More










Filter Sentiment:



All






Positive




Negative





Filter Category:




All






Revenue






Legal





Financial







M & A






Other






Filter Subcategory:




All






Product






Expense






Shares





Earnings







Income






Cash Flow






Geography






Dividend






Other







 Inside Regeneron Pharmaceuticals Inc's 10-K Annual Report:


 Other - Other   Highlight
However, if actual experience differs from the assumptions used in estimating amounts reflected in our Consolidated Financial Statements, the resulting changes could have a material adverse effect on our results of operations, and, in certain situations, could have a material adverse effect on our liquidity and financial condition.



 Other - Other   Highlight
Uncertain tax positions are recorded based upon certain recognition and measurement criteria.

 Other - Other   Highlight
Any failure by us to obtain, or delay in obtaining, regulatory approvals could materially adversely affect our business.

 Other - Other   Highlight
The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurring and for which the specific timing cannot be predicted.

 Revenue - Product   Highlight
Net product sales of EYLEA in the United States decreased in 2023, compared to 2022, primarily due to changing market dynamics, resulting in a lower net selling price and lower volumes.

 Other - Other
Such financial covenants and certain...Read more

 Other - Other
The critical accounting estimates that...Read more

 Legal - Other
Intangible assets are reviewed for...Read more

 Other - Other
A valuation allowance is established...Read more

 Financial - Expense
Clinical manufacturing costs primarily consist...Read more

 Other - Other
The 2022 Credit Agreement contains...Read more

 Legal - Other
Significant judgment is required in...Read more

 Other - Other
We adjust the amount of...Read more

 Other - Other
The 2022 Credit Agreement includes...Read more

 Other - Other
As we discontinued further clinical...Read more

 M & A - Other
Amounts allocated to acquired in-process...Read more

 Other - Other
Additionally, capital expenditures in 2023...Read more

 Legal - Other
Proceeds of the loans under...Read more

 Other - Other
We had no borrowings outstanding...Read more

 Financial - Expense
We believe that our existing...Read more

 Financial - Shares
The share repurchase program permits...Read more

 Other - Other
Definite-lived intangible assets are amortized...Read more

 Revenue - Product
(b) As the A&R IO...Read more

 Financial - Shares
In November 2021, our board...Read more

 Financial - Earnings
The estimates are revised, if...Read more

 Financial - Shares
In January 2021, our board...Read more

 Financial - Shares
"Business - Collaboration, License, and...Read more

 Financial - Shares
In January 2023, our board...Read more

 Other - Other
Indefinite-lived intangible assets are subject...Read more

 Financial - Shares
There can be no assurance...Read more

 Other - Other
We expect continued significant capital...Read more

 Revenue - Product
** Effective April 1, 2021,...Read more

 M & A - Other
Intangible assets acquired in a...Read more

 Financial - Expense
The grant-date fair value of...Read more

 Other - Other
Our research and development efforts...Read more

 Revenue - Product
* Effective July 1, 2022,...Read more

 Other - Other
There can be significant judgment...Read more

 M & A - Other
Payments to acquire intangible assets...Read more

 Revenue - Product
•higher share of profits earned...Read more

 Financial - Earnings
Our ability to generate profits...Read more

 Financial - Expense
Stock-based compensation expense also includes...Read more

 Legal - Other
As additional information becomes available,...Read more

 Revenue - Product
(b) Effective January 1, 2022,...Read more

 Revenue - Product
•royalties earned in connection with...Read more

 Other - Other
We expect to incur capital...Read more

 Financial - Shares
•share in any profits or...Read more

 Financial - Income
The increase in interest income...Read more

 Other - Other
In agreements involving multiple goods...Read more

 Other - Other
The lengthy process of seeking...Read more

 Financial - Income
We periodically re-assess the need...Read more

 Financial - Earnings
•higher reimbursements for the manufacture...Read more

 Financial - Expense
Selling, general, and administrative expenses...Read more

 Financial - Earnings
The increase in our share...Read more

 Other - Other
•$30.0 million up-front payment in connection...Read more

 Financial - Income
We recognize deferred tax assets...Read more

 Other - Other
•$45.0 million up-front payment in...Read more

 Other - Other
Regeneron Pharmaceuticals, Inc. has guaranteed...Read more

 M & A - Other
Acquisitions, net of cash acquired,...Read more

 Other - Other
•$20.0 million opt-in payment in connection...Read more

 M & A - Other
Any excess of the purchase...Read more

 Other - Other
Expected volatility is estimated based...Read more

 Financial - Expense
If there are any changes...Read more

 Other - Other
We have entered into various...Read more

 Other - Other
Liabilities for unrecognized tax benefits...Read more

 Financial - Expense
Under certain of the Company's...Read more

 Other - Other
* Certain prior year amounts...Read more

 Financial - Shares
"Collaboration, License, and Other Agreements,"...Read more

 Other - Other
As of June 30, 2023,...Read more

 Revenue - Product
•receive royalties and/or sales-based milestone...Read more

 Financial - Shares
Therefore, we continue to expect...Read more

 Financial - Shares
As of December 31, 2023, $1.531...Read more

 Other - Other
In addition, we reassess our...Read more

 Financial - Expense
The amount required to fund...Read more

 Other - Other
Management believes the current assumptions...Read more

 Financial - Expense
Cost of goods sold increased...Read more

 Revenue - Product
As of December 31, 2021,...Read more

 Other - Other
The Third Amended and Restated...Read more

 Other - Other
Management's Discussion and Analysis of...Read more

 Other - Other
We recognize the financial statement...Read more

 Other - Other
Due to their nature, there...Read more

 Other - Other
Our collaboration agreements may require...Read more

 Other - Other
As of December 31, 2021, the...Read more

 Other - Other
Other non-cash items, net, in...Read more

 Financial - Cash Flow
If an indicator of impairment...Read more

 Financial - Expense
(b) Includes costs incurred in...Read more

 Revenue - Product
We review our estimates of...Read more

 Other - Other
As set forth in the...Read more

 Other - Other
Certain countries in which we...Read more

 Financial - Expense
We expect to continue to...Read more

 Revenue - Product
The amount of revenue we...Read more

 Other - Other
Regeneron Pharmaceuticals, Inc. is a...Read more

 Financial - Expense
Direct research and development expenses...Read more

 Financial - Expense
If our collaborator performs research...Read more

 Other - Other
The 2022 Credit Agreement includes...Read more

 Financial - Expense
Capital expenditures in 2023 included...Read more

 M & A - Other
If it is determined that...Read more

 Revenue - Geography
The Company's effective tax rate...Read more

 Other - Other
In addition, our products are...Read more

 Revenue - Product
EYLEA volumes in 2023 were...Read more

 Other - Other
In order to determine the...Read more

 Financial - Expense
Reimbursement of development expenses incurred...Read more

 Financial - Expense
Indirect research and development expenses...Read more

 Financial - Expense
We also anticipate continuing to...Read more

 Revenue - Product
Roche distributes and records net...Read more

 Financial - Expense
Commercialization costs over the next...Read more

 Other - Other
While we do not expect...Read more

 Revenue - Product
As of December 31, 2022, Accounts...Read more

 Financial - Expense
We reassess the probability of...Read more

 Financial - Earnings
Global net product sales of...Read more

 M & A - Other
In a business combination, the...Read more

 M & A - Other
In a business combination, contingent...Read more

 M & A - Other
In an asset acquisition, assets...Read more

 Financial - Dividend
The expected dividend yield is...Read more

 Financial - Expense
We capitalize inventory costs associated...Read more

 Revenue - Product
Revenue from product sales is...Read more

 Financial - Expense
We expect to recognize this...Read more

 Other - Other
The agreements governing the Third...Read more

 Financial - Expense
In accordance with the terms...Read more

 Other - Other
Due to the variability in...Read more

 Financial - Expense
We also expect to incur...Read more

 Financial - Expense
(a) Includes costs incurred net...Read more

 Other - Other
We use the Black-Scholes model...Read more

 Other - Other
As of December 31, 2023, our...Read more

 Revenue - Product
As of December 31, 2021,...Read more

 Financial - Income
Other operating (income) expense, net,...Read more

 Financial - Expense
Reimbursement of development expenses incurred...Read more

 Financial - Earnings
Global gross profit payment from...Read more

 Other - Other
If certain batches or units...Read more

 Financial - Expense
As of December 31, 2023 and...Read more

 Financial - Expense
The determination to capitalize inventory...Read more

 Other - Other
Expected lives are principally based...Read more

 Financial - Expense
Reimbursements for manufacturing of commercial...Read more

 Financial - Shares
The assumptions used in computing...Read more

 Financial - Expense
Research and development expenses included...Read more

 Other - Other
Inventory write-offs and reserves were...Read more

 Revenue - Product
Previously, the Company received from...Read more

 Financial - Expense
If we subsequently determine that...Read more

 Revenue - Product
Other revenue in 2023 included...Read more

 Financial - Shares
Repurchases may be made from...Read more

 Financial - Expense
•supply commercial product to our...Read more

 Financial - Cash Flow
If the projected undiscounted cash...Read more

 Financial - Shares
Our collaborators provide us with...Read more

 Legal - Other
We accrue, based on management's...Read more

 Other - Other
It is uncertain whether the...Read more

 Financial - Expense
The amount of funding that...Read more

 Financial - Earnings
Our financial results may fluctuate...Read more

 Financial - Shares
These reimbursements are deducted each...Read more

 Financial - Expense
The estimates are revised, if...Read more

 Revenue - Product
Amounts borrowed under the 2022...Read more

 Other - Other
Changes in any of these...Read more

 Financial - Expense
We expect to continue to...Read more

 Financial - Expense
Cost of collaboration and contract...Read more

 Financial - Expense
We expect that expenses related...Read more

 M & A - Other
We make certain judgments to...Read more

 Financial - Expense
We recognize stock-based compensation expense...Read more

 Other - Other
The 2022 Credit Agreement also...Read more

 Revenue - Product
We are unable to reasonably...Read more

 Financial - Expense
Selling, general, and administrative expenses...Read more

 Financial - Expense
(a) Corresponding costs incurred by...Read more

 Financial - Expense
(a) Corresponding costs incurred by...Read more

 Financial - Expense
Operating expenses in 2023 and...Read more

 Financial - Expense
If contingent consideration is recognized...Read more

 Other - Other
•$30.0 million charge to extend...Read more

 Financial - Expense
There is also variability in...Read more

 Financial - Expense
For performance-based restricted stock units...Read more

 Revenue - Product
With regard to contingent consideration...Read more

 Revenue - Product
During the year ended December 31,...Read more

 Other - Other
This estimate is revised, if...Read more

 Revenue - Product
We periodically analyze our inventory...Read more

 Other - Other
Deferred tax assets and liabilities...Read more

 Financial - Expense
Clinical manufacturing costs also includes...Read more

 Revenue - Product
We recognize revenue from product...Read more

 Financial - Expense
In addition, our research and...Read more

 Other - Other
•$100.0 million charge in connection...Read more

 Other - Other
This estimate is based upon...Read more

 Financial - Expense
This increase was partly offset...Read more

 Other - Other
The fair value of contingent...Read more

 Other - Other
We were in compliance with...Read more

 Other - Other
We use a Monte Carlo...Read more

 Financial - Expense
Our collaborators provide us with...Read more



 
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report





Audit Information





Cover





Consolidated Balance Sheets





Consolidated Balance Sheets (Parenthetical)





Consolidated Statements Of Cash Flows





Consolidated Statements Of Operations And Comprehensive Income





Consolidated Statements Of Stockholders' Equity





Accrued Expenses And Other Current Liabilities





Accrued Expenses And Other Current Liabilities (Tables)





Accrued Expenses And Other Current Liabilities - Schedule Of Accrued Expenses And Other Current Liabilities (Details)





Business Overview And Summary Of Significant Accounting Policies





Business Overview And Summary Of Significant Accounting Policies (Policies)





Business Overview And Summary Of Significant Accounting Policies (Tables)





Business Overview And Summary Of Significant Accounting Policies - Narrative (Details)





Business Overview And Summary Of Significant Accounting Policies - Schedule Of Estimated Useful Lives (Details)





Collaboration, License, And Other Agreements





Collaboration, License, And Other Agreements (Tables)





Collaboration, License, And Other Agreements - Alnylam Narratives (Details)





Collaboration, License, And Other Agreements - Amounts Recognized In Statement Of Operations With Alnylam (Details)





Collaboration, License, And Other Agreements - Amounts Recognized In Statement Of Operations With Alnylam (Details)





Collaboration, License, And Other Agreements - Amounts Recognized In Statement Of Operations With Roche (Details)





Collaboration, License, And Other Agreements - Bayer Narrative (Details)





Collaboration, License, And Other Agreements - Checkmate Narrative (Details)





Collaboration, License, And Other Agreements - Decibel Narrative (Details)





Collaboration, License, And Other Agreements - Intellia Narrative (Details)





Collaboration, License, And Other Agreements - Other Narrative (Details)





Collaboration, License, And Other Agreements - Sanofi, Antibody Narrative (Details)





Collaboration, License, And Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)





Collaboration, License, And Other Agreements - Schedule Of Accounts Receivable And Deferred Revenue Information, Antibody Collaboration (Details)





Collaboration, License, And Other Agreements - Schedule Of Collaboration Revenue Earned From Bayer (Details)





Collaboration, License, And Other Agreements - Schedule Of Collaboration Revenue Earned From Sanofi (Details)





Collaboration, License, And Other Agreements - Schedule Of Contract Balances, Alnylam Collaboration (Details)





Collaboration, License, And Other Agreements - Schedule Of Contract Balances, Alnylam Collaboration (Details)





Collaboration, License, And Other Agreements - Schedule Of Contract Balances, Bayer Collaborative (Details)





Collaboration, License, And Other Agreements - Schedule Of Contract Balances, Roche Collaboration (Details)





Collaboration, License, And Other Agreements - Schedule Of Contract Balances, U.S. Government (Details)





Collaboration, License, And Other Agreements - Sonoma Narrative (Details)





Collaboration, License, And Other Agreements - Summary Of Assets Acquired And Liabilities Assumed, Decibel (Details)





Collaboration, License, And Other Agreements - U.S. Government Narrative (Details)





Debt





Debt (Tables)





Debt - Narrative (Details)





Debt - Summary Of Issued Senior Unsecured Notes (Details)





Employee Savings Plans





Employee Savings Plans (Details)





Fair Value Measurements





Fair Value Measurements (Tables)





Fair Value Measurements - Narrative (Details)





Fair Value Measurements - Schedule Of Assets Measured At Fair Value On A Recurring Basis (Details)





Income Taxes





Income Taxes (Tables)





Income Taxes - Narrative (Details)





Income Taxes - Schedule Of Components Of Income Tax Expense (Details)





Income Taxes - Schedule Of Deferred Tax Assets And Liabilities (Details)





Income Taxes - Schedule Of Effective Income Tax Rate Reconciliation (Details)





Income Taxes - Schedule Of Income Before Income Tax (Details)





Income Taxes - Schedule Of Unrecognized Tax Benefits (Details)





Insider Trading Arrangements





Intangible Assets





Intangible Assets (Tables)





Intangible Assets - Narrative (Details)





Intangible Assets - Schedule Of Intangible Assets (Details)





Inventories





Inventories (Tables)





Inventories - Narrative (Details)





Inventories - Schedule Of Inventories (Details)





Leases





Leases (Tables)





Leases - Amounts Recognized In Condensed Consolidated Balance Sheet (Details)





Leases - Analysis Of Lease Liability Maturities (Details)





Leases - Finance Lease Costs (Details)





Leases - Leases Narrative (Details)





Leases - Other Information Related To Finance Lease (Details)





Leases - Supplemental Cash Flows (Details)





Legal Matters





Legal Matters (Details)





Legal Matters (Tables)





Long-Term Incentive Plans





Long-Term Incentive Plans (Tables)





Long-Term Incentive Plans - Narrative (Details)





Long-Term Incentive Plans - Summary Of Activity Related To Performance-Based Awards (Details)





Long-Term Incentive Plans - Summary Of Activity Related To Restricted Stock Awards (Details)





Long-Term Incentive Plans - Summary Of Transactions Involving Stock Option Awards (Details)





Long-Term Incentive Plans - Summary Of Weighted-Average Exercise Prices And Weighted-Average Grant-Date Fair Values Of Options Issued (Details)





Long-Term Incentive Plans - Summary Of Weighted-Average Values Of Assumptions Used In Computing Fair Value Of Option Grants (Details)





Long-Term Incentive Plans - Summary Of Weighted-Average Values Of Assumptions Used In Computing Fair Value Of Performance-Based Options (Details)





Marketable Securities





Marketable Securities (Tables)





Marketable Securities - Narrative (Details)





Marketable Securities - Schedule Of Debt Securities Based On Contractual Maturity Dates (Details)





Marketable Securities - Schedule Of Fair Value And Unrealized Losses Of Debt Securities (Details)





Marketable Securities - Schedule Of Investments In Available For Sale Debt Securities (Details)





Net Income Per Share





Net Income Per Share (Tables)





Net Income Per Share - Schedule Of Antidilutive Securities Excluded From Computation (Details)





Net Income Per Share - Schedule Of Basic And Diluted Net Income Per Share (Details)





Pay Vs Performance Disclosure





Product Sales





Product Sales (Tables)





Product Sales - Narrative (Details)





Product Sales - Schedule Of Concentration Of Risk, By Risk Factor (Details)





Product Sales - Schedule Of Net Product Sales (Details)





Product Sales - Schedule Of Sales Related Deductions Activity (Details)





Property, Plant, And Equipment





Property, Plant, And Equipment (Tables)





Property, Plant, And Equipment - Narrative (Details)





Property, Plant, And Equipment - Schedule Of Property, Plant, And Equipment (Details)





Statement Of Cash Flows





Statement Of Cash Flows (Tables)





Statement Of Cash Flows - Schedule Of Reconciliation Of Cash, Cash Equivalents, And Restricted Cash (Details)





Statement Of Cash Flows - Summary Of Non-Cash Investing And Financing Activities (Details)





Stockholders' Equity





Stockholders' Equity (Tables)





Stockholders' Equity - Narrative (Details)





Stockholders' Equity - Schedule Of Repurchased Shares (Details)




 
Material Contracts, Statements, Certifications & more
Regeneron Pharmaceuticals Inc provided additional information to their SEC Filing as exhibits





Exhibit 10.3 6: Stock Option Agreement (Nq) - Executive Officers





Exhibit 10.3 7: Restricted Stock Agreement - Executive Officers





Exhibit 21.1: Subsidiaries Of The Registrant





Exhibit 23.1: Consent Of Pricewaterhousecoopers Llp





Exhibit 31.1: Certification Of Ceo Pursuant To Rule 13A-14(A)





Exhibit 31.2: Certification Of Cfo Pursuant To Rule 13A-14(A)





Exhibit 32: Certification Of Ceo And Cfo Pursuant To 18 U.S.C. Section 1350





Exhibit 97.1: Clawback Policy






Ticker: REGN CIK: 872589
Form Type: 10-K Annual Report
Accession Number: 0001804220-24-000009
Submitted to the SEC: Mon Feb 05 2024 9:16:15 AM EST
Accepted by the SEC: Mon Feb 05 2024
Period:  Sunday, December 31, 2023
Industry: Pharmaceutical Preparations						
External Resources:
 Stock Quote
 Social Media
 SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/regn/0001804220-24-000009.htm








About 
											Contact 
											Help 
											API 
											Privacy 
											Terms 
									


© 2012 - 2024 Last10K.com All Rights Reserved









×
You're Signed Out
Sign in for the full experience


Sign in
Join Now








Intrinsic Value Calculator








Screenshot of intrinsic value for AT&T (2019)




Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not
Continue












Never Miss A New SEC Filing Again








Screenshot taken from Gmail for a new 10-K Annual Report




Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news
Continue












We Highlighted This SEC Filing For You








Screenshot taken from Wynn's 2018 10-K Annual Report




Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q
Continue












Widen Your SEC Filing Reading Experience








Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report




Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view
Continue












Uncover Actionable Information Inside SEC Filings








Screenshot taken from Lumber Liquidators 10-K Annual Report




Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q
Continue












Adobe PDF, Microsoft Word, Excel and CSV Downloads








Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats




Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis
Continue












Adobe PDF, Microsoft Word, Excel and CSV Downloads








Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats




Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis
Continue












Financial Stability Report








Screenshot of financial stability report for Coco-Cola (2019)




Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity
Continue












Get a Better Picture of a Company's Performance








Available Financial Ratios




Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years
Continue












See when company executives buy or sell their own stock








Screenshot taken from Euronet (EEFT)




Last10K.com Member Feature

Use our calculated cost dollar values to discover when and how much registered owners BUY, SELL or excercise their company stock OPTIONS aggregated from Form 4 Insider Transactions SEC Filings
Continue












See how institutional managers trade a stock








Screenshot taken from General Motors (GM)




Last10K.com Member Feature

View which hedge funds, pension / retirement funds, endowments, banks and insurance companies have increased or decreased their positions in a particular stock. Includes Ownership Percent, Buy versus Sell comparison, Put-Call ratio and more
Continue












FREE Financial Statements








Screenshot of actual balance sheet from company 10-K Annual Report




Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports
Continue for FREE












SEC Filing Exhibit
 PDF Download



Loading SEC Filing Exhibit...








SEC Filing Financial Summary
 PDF Download
 Excel Download



Loading SEC Filing Financial Summary...

